What are the symptoms of prostate cancer and how common is it? - Formula One team owner Eddie Jordan has died from the ...

In the study, Pluvicto (lutetium Lu 177 vipivotide tetraxetan) reduced the risk of radiographic progression or death by 59% ...

Novartis’ radioligand therapy Pluvicto (lutetium Lu 177 vipivotide tetraxetan) has been approved by the US Food and Drug ...

11, 2025 — Researchers have discovered a new mechanism that is used by a male sex hormone ... Radiation Therapy Reduces Long-Term Side Effects for Patients With Prostate Cancer Nov. 13, 2024 ...

Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer, tripling the number of patients ...

Discover recent research that suggests that precision treatment may improve outcomes in prostate cancer treatment.

Truqap combination in PTEN-deficient metastatic hormone-sensitive prostate cancer demonstrated statistically significant and ...

After much delay, Novartis has finally won a key FDA go-ahead for Pluvicto, opening up the radioligand therapy to a much ...

Basel: Novartis has announced that the US Food and Drug Administration (FDA) has approved Pluvicto (lutetium Lu 177 ...

“Prostate-specific membrane antigen (PSMA) PET imaging can identify patients suitable for PSMA-targeted radioligand therapy such as lutetium-177-PSMA-617. This is crucial for mCRPC patients who have ...

Researchers evaluated links between lifestyle and dietary index scores and risk of death in a prospective, multiethnic cohort of men diagnosed with non-metastatic prostate cancer.